亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.

作者
Martin Jean Schlumberger,Rossella Elisei,Stefan P Müller,Patrick Schöffski,Marcia S. Brose,Manisha H. Shah,Lisa Francesca Licitra,Barbara Jarząb,В. С. Медведев,Michael Christoph Kreissl,Ezra E.W. Cohen,Lori J. Wirth,Haythem Y. Ali,Colin Hessel,Yifah Yaron,Douglas Wilmot Ball,Barry D. Nelkin,Steven I. Sherman
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:33 (15_suppl): 6012-6012 被引量:33
标识
DOI:10.1200/jco.2015.33.15_suppl.6012
摘要

6012 Background: Cabo inhibits tyrosine kinases including MET, VEGFR2, and RET. EXAM, a randomized double-blind placebo (P)-controlled study in patients (pts) with progressive, locally advanced, or metastatic MTC (NCT00704730), met its primary end point with a statistically significant improvement in progression-free survival (PFS) (hazard ratio [HR] = 0.28, p < 0.001) (Elisei et al, JCO, 2013). This report contains the final analysis of the secondary endpoint, Overall Survival (OS). Methods: Eligible pts were required to have documented RECIST progression within 14 months (mo) of screening, and were randomized 2:1 to receive Cabo (140 mg qd) or P. Crossover between treatment arms was not allowed. The primary endpoint was PFS assessed by RECIST via independent review. The study was designed with 80% power to detect a HR of 0.667 for the secondary endpoint of OS. Results: At the final analysis, median follow up time was 52.4 mo. 218 events were recorded in the intent-to-treat (ITT) population (N = 330). The estimated median OS was 26.6 mo for Cabo vs 21.1 mo for P (stratified HR = 0.85; 95% CI 0.64-1.12; p = 0.241). For 126 pts with known RET M918T mutations, median OS was 44.3 mo for Cabo vs 18.9 mo for P (HR = 0.60, p = 0.026). 32% of Cabo-treated pts received subsequent systemic anticancer therapy vs 50% for P-treated pts. The median duration of treatment was 10.8 mo for Cabo and 3.5 mo for P. 46% and 26% of Cabo-treated pts remained on study treatment for over 1 year and 2 years, and 10% and 1.8% for P, respectively. The most common serious adverse events ( ≥ 2%) on the Cabo arm were pneumonia (4.2%), pulmonary embolism (3.3%), mucosal inflammation (2.8%), hypocalcemia (2.8%), hypertension, dysphagia, dehydration and lung abscess (2.3% each). Conclusions: The secondary endpoint of improved OS was not met, with a median OS 5.5 mo longer with Cabo compared to P that did not reach significance in the ITT population. OS improvement with Cabo was greatest in patients with RET M918T mutations, with a 25.4-month increase in median OS compared to P. The safety profile of Cabo remained consistent with longer term exposure. Clinical trial information: NCT00704730.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
14秒前
朝与暮完成签到,获得积分10
16秒前
25秒前
32秒前
32秒前
顾矜的应助被雪白的听寒采纳,获得10
38秒前
38秒前
may发布了新的文献求助10
39秒前
深情安青的应助被昏睡的映阳采纳,获得10
49秒前
59秒前
Nobodyet发布了新的文献求助10
1分钟前
迷人白桃完成签到,获得积分10
1分钟前
科研通AI2S的应助被小邹采纳,获得10
1分钟前
Wd完成签到,获得积分10
1分钟前
1分钟前
1分钟前
YUAN完成签到,获得积分10
1分钟前
SunJay完成签到 ,获得积分10
1分钟前
文艺夜白完成签到,获得积分10
1分钟前
程生完成签到,获得积分10
1分钟前
小貉完成签到,获得积分10
1分钟前
2分钟前
小邹发布了新的文献求助10
2分钟前
fpy完成签到,获得积分10
2分钟前
wx完成签到,获得积分10
2分钟前
清爽老九发布了新的文献求助10
2分钟前
2分钟前
单纯寄云完成签到,获得积分10
2分钟前
澹青云完成签到 ,获得积分10
2分钟前
清爽老九完成签到,获得积分0
2分钟前
Nobodyet完成签到,获得积分10
2分钟前
江蹇完成签到,获得积分10
2分钟前
深情安青的应助被小邹采纳,获得10
2分钟前
1874发布了新的文献求助100
2分钟前
受不了12345完成签到,获得积分10
2分钟前
2分钟前
petrichor发布了新的文献求助10
3分钟前
3分钟前
大猩猩发布了新的文献求助30
3分钟前
之桃完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190113
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852162
捐赠科研通 7788317
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559990
邀请新用户注册赠送积分活动 2482862